Durata Plans To Pitch Dalbavancin As Cost-Saving Paradigm Changer
Company plans to file an NDA for the antibiotic in September, built partly on clinical work done by the drug’s previous owner, Pfizer. Given hospitals’ emphasis on cost, Durata’s marketing plan will highlight the drug’s two-dose regimen, which could help move treatment to the ambulatory-care setting.
You may also be interested in...
The novel antibiotic will fit well into a treatment paradigm moving more toward outpatient care, The Medicines Co. execs explained to investors. The firm will stress cost savings, reduced need for hospitalization and a virtual guarantee of patient compliance.
Company is banking on its single-dose treatment course to propel it over competitors in a crowded generic and branded space, but this may involve major changes in treatment practice, analysts say.
Second QIDP antibiotic is first to market; Cubist will stress shorter term dosing over available therapies and thinks it can rely on efficient marketing strategy for commercial success.